Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Bright Minds Biosciences Inc (DRUG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/16/2025: DRUG (3-star) is a STRONG-BUY. BUY since 14 days. Simulated Profits (42.06%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $95.47
1 Year Target Price $95.47
| 4 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 4373.9% | Avg. Invested days 42 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 12/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 607.28M USD | Price to earnings Ratio - | 1Y Target Price 95.47 |
Price to earnings Ratio - | 1Y Target Price 95.47 | ||
Volume (30-day avg) 6 | Beta -0.53 | 52 Weeks Range 23.18 - 97.75 | Updated Date 12/16/2025 |
52 Weeks Range 23.18 - 97.75 | Updated Date 12/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -18.31% | Return on Equity (TTM) -30.79% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 558476549 | Price to Sales(TTM) - |
Enterprise Value 558476549 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.07 | Shares Outstanding 7088639 | Shares Floating 2995031 |
Shares Outstanding 7088639 | Shares Floating 2995031 | ||
Percent Insiders 20.4 | Percent Institutions 78.89 |
About Bright Minds Biosciences Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2021-03-22 | Co-Founder, CEO, President & Director Mr. Ian McDonald | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://brightmindsbio.com |
Full time employees - | Website https://brightmindsbio.com | ||
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatry and neurology indications. Bright Minds Biosciences Inc. has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was founded in 2017 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.